– USA, CA – ACELYRIN, INC., a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced the appointment of Dawn Svoronos to its board of directors, bringing to the Board extensive industry expertise including nearly 25 years of executive commercial leadership experience gained at Merck & Co. Inc.
“I am delighted to welcome Dawn to our board of directors. Her proven success as a commercial leader in both the US and globally will be particularly valuable to ACELYRIN as we move our late-stage pipeline toward commercialization.” said co-founder and CEO, Dr. Shao-Lee Lin.
About Dawn Svoronos
Prior to her retirement from Merck in 2011, she served as President of Europe/Canada, President of Canada, VP of Asia Pacific and Head of Global Marketing for the Arthritis, Analgesics and Osteoporosis franchises. During her career, Ms. Svoronos has led teams managing the global brand positioning, market and competitive intelligence, pricing and lifecycle strategies for many products across multiple therapeutic areas. Additionally, in 2014, while a member of the board of directors for Medivation Inc., she also served as interim CCO and oversaw sales and marketing of the company’s blockbuster oncology therapy, XTANDI.
Ms. Svoronos also has extensive experience as a corporate director in the biotechnology sector for both public and private companies. She is currently Chair of the Board for Theratechnologies Inc., Lead Independent Director for Xenon Pharmaceuticals Inc. (XENE) and member of the board for Adverum Biotechnologies Inc. Ms. Svoronos is also a member of the board of Agnovos Bioscience, a privately held organization in New York. She was previously a director of Medivation prior to its acquisition by Pfizer, a director of Global Blood Therapeutics prior to its acquisition by Pfizer, a director of Endocyte Inc. prior to its acquisition by Novartis, and a director of PTC Therapeutics Inc.
“I am pleased to join the ACELYRIN Board of Directors at this exciting time for the company,” said Dawn Svoronos. “With multiple late-stage clinical trials underway, I look forward to working with Shao-Lee and her leadership team to bring my experience to ACELYRIN in preparing for commercialization of izokibep and other future therapies.”
Ms. Svoronos received a BA from Carleton University in Ottawa, Ontario, Canada.
About ACELYRIN
ACELYRIN, INC. is a Los Angeles area-based biopharma company – with additional operations in the San Francisco Bay area – focused on providing patients life-changing new treatment options by identifying, acquiring, and accelerating development and commercialization of promising drug candidates and leveraging its expertise to rapidly advance these medicines to patients. Under an exclusive licensing arrangement with Affibody AB, ACELYRIN holds global development and commercialization rights to izokibep, including in the United States, European Union, and Japan (excluding select Asian countries).
For more information : https://acelyrin.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.